Management of Allergic Asthma with Shrishadi Agad followed by Amalaki Rasayana as Add on Treatment

Author:

Sharma Pooja,Sharma Nitin,Kajaria Divya

Abstract

Allergic asthma (AA) is the most common form of asthma. An allergy is when the immune system mistakes a harmless substance, such as pollen, dust, and mites. The body releases chemicals to attack the substance and can lead to asthma symptoms such as wheezing, chest tightness, difficulty in breathing, and coughing that can vary over time. A 23-year-old female was diagnosed with AA since 2011 by an allopathic consultant in Delhi. She was regularly treated with short-acting bronchodilators (Levalbuterol) inhaler. Shrishadi Agad is a formulation described in the textbook of Shusruta Samhita which contains Shirish Chaal (Albizia lebbeck), Trikatu Churna, Madhu (∼Honey), and Saindhava lavan (∼Rock salt) which are in totality responsible for its Vishaghna (Anti-toxic) properties. The patient was considered suffering from Santamak Shwasa (∼AA) on the bases of International Classification of Diseases (ICDs)-11 and was treated with Shrishadi Agad twice a daily along with Haritaki Churna, bedtime for 1 month followed by Amalaki Rasayan in the dose of 3 g, twice a day for 2 months. On the basis of the same medication, regular follow-up was taken up to assess the health of the patient. After 3 months of treatment, the patient showed significant improvement in sneezing, breathlessness, cough, and generalized weakness. There is a significant decrease in the range of immunoglobulin E (from 3000 IU/ml to 1493 IU/ml), absolute eosinophil count (from 720/cu.mm. to 228/cu.mm.), and pulmonary parameters (i.e., forced expiratory volume in and forced vital capacity) also shows respective changes. This case shows that Shrishadi agad followed by Amalaki Rasayana is effective in the management of AA on the basis of ICD-11 diagnostic criteria AA modern and Ayurvedic diagnostic criteria.

Publisher

Medknow

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3